Dr. R. D. Andrews,
Department of Health & Social Security,
Medicines Division,
Finsbury Square,House,
33/37a Finsbury Square,
London EC2A 1PP.

15th September, 1975
NB/jb

Dear Dr. Andrews,

Since we first started selling Factor VIII and Factor IX Concentrate in 1973 you will, I am sure agree, that our products have gained a good reputation for freedom from adverse reactions especially Serum Hepatitis. This view is supported by the greatly increased demand.

This good track record has undoubtedly been due to the use of donors from low incidence areas, and the checking of their individual donations, pooled plasma and final product for absence of Australian Antigen.

As stipulated in the protocols we submit to Dr. Magrath, donors and the donations are tested by cross-over electrophoresis. Pooled plasma by cross-over electrophoresis.and RIA are the final product by RIA.

As however, testing methods continue to improve we have for more than a year been looking for opportunities to improve our screening methods. In the first place, the relatively new haemagglutination methods were considered and tested but were not regarded as giving complete satisfaction.

In consequence orders were placed for the necessary additional equipment to institute RIA testing of each individual donation.

Immuno are on the verge of implementing their decision whereon, once the pipe line is cleared, material will begin to emerge which has been TIA tested at each stage. This will of course be indicated on the first and subsequent protocols submitted to MRC.

continued .....

I will be pleased if you will accept this as advanced notice of this improvement in our method for preparing Kryobulin (0215/0003) and Prothomplex (0215/006/007/008).

Yours sincerely,
for SEROLOGICAL PRODUCTS LIMITED

GRO-C

Managing Director

c.c.Dr. J. A. Holgate